Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

- University of Oxford, in partnership with the Duke Clinical Research Institute, to assess effect of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease

- EMPA-KIDNEY will be part of the empagliflozin clinical development program which explores the efficacy and safety of Jardiance across a broad spectrum of patients and clinical conditions

Ridgefield, Conn. and Indianapolis., Boehringer Ingelheim and Eli Lilly and Company today announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance®on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical Research Council Population Health Research Unit at the University of Oxford (MRC PHRU), which is based in the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), in partnership with the Duke Clinical Research Institute. Boehringer Ingelheim and Lilly will provide the funding for the study.

The plan to conduct a dedicated outcomes study in adults with chronic kidney disease is based on insights previously obtained from the EMPA-REG OUTCOME® trial. This landmark trial investigated the effect of Jardiance, when added to the standard of care, on cardiovascular outcomes in adults with type 2 diabetes and established cardiovascular disease, compared with placebo. Approximately one third of patients in the EMPA-REG OUTCOME trial also had established chronic kidney disease at baseline. A secondary exploratory endpoint of the study provided promising data relating to the reduction in the relative risk of new onset or worsening kidney disease. EMPA-KIDNEY will help further our understanding of these data.

“We need to explore new treatment options that can help slow the progression of chronic kidney disease, given that 30 million adults in the United States are living with this condition,” said Jennifer Green, M.D., endocrinologist and associate professor of medicine at the Duke Clinical Research Institute, which is responsible for U.S. trial operations. “The EMPA-REG OUTCOME trial findings prompted us to explore further the effects of empagliflozin on the risk of new or worsening kidney disease in adults with type 2 diabetes and established cardiovascular disease. Now, EMPA-KIDNEY will examine whether empagliflozin has the potential to be a new treatment option for people with chronic kidney disease.”

EMPA-KIDNEY will include approximately 5,000 adults with established chronic kidney disease, with and without diabetes. The primary outcome of the study is to assess the effect of Jardiance on time to clinically relevant kidney disease progression or cardiovascular death. The study will be part of the empagliflozin clinical development program, the largest clinical development program of an SGLT2 inhibitor.

“Boehringer Ingelheim and Lilly are committed to exploring how Jardiance can potentially fill gaps where unmet treatment needs exist,” said Thomas Seck, M.D., vice president of Clinical Development and Medical Affairs – Primary Care, Boehringer Ingelheim Pharmaceuticals, Inc. “Given the institution’s knowledge and history of prestigious research in chronic kidney disease, we are excited to collaborate with the University of Oxford on this initiative to help address a pressing need for people with chronic kidney disease.” 

“The EMPA-KIDNEY study, which will build on results of the EMPA-REG OUTCOME trial, will continue to expand our understanding of how Jardiance can impact the lives of a broad range of people with and without diabetes,” said Jeff Emmick, M.D., Ph.D., vice president, Product Development, Lilly Diabetes. “We look forward to this new partnership and the opportunity to follow the progress of the EMPA-KIDNEY study.”

About the MRC PHRU at the University of Oxford

The focus of MRC PHRU at the University of Oxford (https://www.mrc-phru.ox.ac.uk/(link is external)), which is led by Professor Colin Baigent, is to improve treatment and prevention of chronic diseases, particularly cardiovascular disease and metabolic disease (e.g. diabetes mellitus and chronic kidney disease), which collectively account for a large proportion of premature adult deaths and the burden of disability worldwide. MRC PHRU leads innovative clinical trials and meta-analyses to identify important advances that could have a major impact on health. Its worldwide approach, involving the study of large numbers of people, provides reliable information about the causes of disease and the effects of treatments, which can have a major impact on global health.

About EMPA-KIDNEY: The study of heart and kidney protection with empagliflozin

EMPA-KIDNEY is a multinational randomized, double-blind, placebo-controlled clinical trial. It is designed to evaluate the effect of empagliflozin on clinically relevant outcomes: kidney disease progression and cardiovascular mortality risk. The primary outcome is defined as time to a first event of either a cardiovascular death or kidney disease progression, defined as end stage kidney disease (the need for kidney replacement therapy such as, dialysis or kidney transplantation), a sustained decline in eGFR to <10mL/min/1.73m2, renal death or a sustained decline of ≥40% in eGFR from randomization. EMPA-KIDNEY will include people with established chronic kidney disease both with and without diabetes receiving current standard of care.  

The study will be conducted in selected countries representing a global footprint and aims to randomize approximately 5,000 participants to receive either empagliflozin 10 mg once daily or placebo, on top of standard of care.

Sources
  • Boehringer Ingelheim and Eli Lilly and Company

Comments